Close Menu

NEW YORK — Dutch diagnostics firm SkylineDx said on Monday that it has received a €20 million ($21.9 million) investment to further develop its melanoma test.

The funding is being provided by private investor Aat van Herk, and will be used to perform clinical testing of an assay — developed in collaboration with the Mayo Clinic — designed to predict the risk of a melanoma patient's cancer metastasizing in lymph nodes without the need for biopsy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.